Biogen Q3 results better than expected, updrades guidance

The US-based biotech company Biogen has released its Q3 report for 2021, stating that sales and revenue decrease was smaller than expected – subsequently, financial guidance is upgraded.

Photo: Brian Snyder/Reuters/Ritzau Scanpix

The US premarket indicator for Biogen stock is up 1.8 percent at USD 273.

This in spite of Biogen's total Q3 revenue drop of 18 percent, ending at USD 2.78bn – thus over analysts' estimates of USD 2.68bn.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs